Amezinium methylsulfate (Lu-1631) has multiple mechanisms, including stimulation of alpha and beta-1 receptors and inhibition of noradrenaline and tyramine uptake.

在5名多系统萎缩症患者中，使用每日15 mg的amezinium metilsulfate（一种肾上腺素能化合物）治疗姿势性低血压6个月，与治疗前相比，治疗后排尿后残余量明显增加（治疗前113 ml，治疗后178 ml，变化率为37%）[1]。amezinium明显提高了FTBF的减少比率（安慰剂75.9%；amezinium 85.1%；midodrine 78.1%]。amezinium显著降低了产生半最大静脉收缩的去甲肾上腺素的输注速率（安慰剂40.6 ng/min；amezinium 21.0 ng/min）[2]。